Table 1.
Patient demographics and antiretroviral regimens
| Characteristic | n (%) or median (IQR) |
|---|---|
| Sex | |
| Male | 70 (89) |
| Female | 9 (11) |
| Age (years) | 44 (34.5 to 53) |
| Cumulative TDF exposure (years) | 3.5 (1.5 to 4.75) |
| Pre-switch TDF regimen | |
| TDF/FTC/† | 38 (48) |
| TDF/FTC/RPV | 18 (23) |
| TDF/FTC/EFV | 15 (19) |
| TDF/FTC/E/COBI | 8 (10) |
| Post-switch TAF regimen | |
| TAF/FTC/† | 57 (72) |
| TAF/FTC/RPV | 12 (15) |
| TAF/FTC/E/COBI | 10 (13) |
COBI cobicistat, E elvitegravir, EFV efavirenz, eGFR estimated glomerular filtration rate, FTC emtricitabine, RPV rilpivirine, TAF tenofovir alafenamide, TDF tenofovir disoproxil fumarate
†These regimens contained a third agent not otherwise listed in the table. In over three quarters of patients, both pre- and post-switch, the third agent was dolutegravir